Puromycin aminonucleoside (Synonyms: NSC 3056, PANS) |
カタログ番号GC10171 |
糸球体上皮細胞毒素
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 58-60-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
Madin-Darby canine kidney (MDCK) cells |
Preparation method |
The solubility of this compound in DMSO is >14.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
48 h |
Applications |
In vector- and PMAT-transfected MDCK cells, Puromycin aminonucleoside (PAN) exhibited cell cytotoxicity with the IC50 values of 48.9 ± 2.8 and 122.1 ± 14.5 μM, respectively. PAN (250 μM) was toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside uptake in PMAT-expressing cells was four fold higher at pH 6.6 than that at pH 7.4. |
Animal experiment [2,3]: | |
Animal models |
Nephrosis rats |
Dosage form |
Intravenous injection, 60 mg/kg, 150 mg/kg |
Application |
In nephrosis rats, the number of podocytes per glomerulus was 90.7 on Day 4 in PAN (8 mg/100 g, i.v.) treated group. The amount of nephrin per glomerulus in PAN-treated nephrosis rats reduced to 0.46 ± 0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte was significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats. Rats given PAN (100 mg/kg, s.c.) gained less weight and their serum creatinine levels were higher than the control rats, indicating Puromycin aminonucleoside impaired renal function. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Xia L, Zhou M, Kalhorn T F, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. American Journal of Physiology-Renal Physiology, 2009, 296(6): F1307-F1313. [2]. Kawakami, Hirotaka, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrology Dialysis Transplantation 27.4 (2011): 1324-1330. [3]. Nosaka, Kazuo, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radical Biology and Medicine 22.4 (1997): 597-605. |
IC50:不明
プロマイシンアミノヌクレオシド、3'-アミノ-3'-デオキシ-N6、N6-ジメチルアデノシンは、抗生物質プロマイシンのアミノニュクレオシド部分です。ラットにおけるプロマイシンアミノニュクレオシド(PAN)誘発性腎症は、重度のタンパク尿症の病態を調べるための模型となります。
インビトロ:以前の研究では、赤血球糸球体細胞に対するPANのインビトロ効果を調べるために、走査型電子顕微鏡(SEM)と透過型電子顕微鏡(TEM)を使用しました。ラットの腎臓スライスはPANで培養されました。腎臓スライス上の糸球体のSEM分析では、PANと培養した場合、ポドサイト細胞体上のマイクロビリ数が減少し、糸球体数が増加したことが示されました。 TEM形態計測では、コントロールグループで観察されたポドサイト足プロセスの喪失を有意に遅らせることが示されました[1]。
In vivo:Wistarラットでは、PANの複数回注射により持続的な重度のタンパク尿とFSGHS病変がグロメルリに生じました。一方、PVG/cラットでは、慢性タンパク尿を誘発するためにより高いPAN投与量が必要でした。単回静脈注射による急性PAN腎症では、Wistarラットのメサンギウムは多くの脂質を示し、ネフローゼ性PVG/cラットではわずかな小さなメサンギアル脂質滴が見られました。また、ネフローゼ性PVG/cラットへコロイダルカーボンを注入後も非タンパク尿群と比較してメサンギウム内で増強されたカーボン集積は観察されませんでした[2]。
臨床試験:N/A
IC50:N/A
IC50: N/AReferences:
[1] Grond J,Muller EW,van Goor H,Weening JJ,Elema JD.? Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int.1988 Feb;33(2):524-9.
[2] Bertram JF,Messina A,Ryan GB.? In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes. Cell Tissue Res.1990 May;260(3):555-63.
Cas No. | 58-60-6 | SDF | |
同義語 | NSC 3056, PANS | ||
Chemical Name | 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol | ||
Canonical SMILES | CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O | ||
Formula | C12H18N6O3 | M.Wt | 294.31 |
溶解度 | ≥ 14.45 mg/mL in DMSO, ≥ 29.4 mg/mL in EtOH with gentle warming, ≥ 29.5 mg/mL in Water with gentle warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3978 mL | 16.9889 mL | 33.9778 mL |
5 mM | 0.6796 mL | 3.3978 mL | 6.7956 mL |
10 mM | 0.3398 mL | 1.6989 mL | 3.3978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *